From centredaily.com
()
Wellstat Therapeutics Corporation and sanofi-aventis (EURONEXT: SAN)(NYSE: SNY) announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes. PN2034 was discovered by Wellstat and is currently in Phase II clinical trials to reverse insulin resistance in the liver of diabetic patients.
Comments
Be the first to leave a comment!
People in Pictures
Top Wellness Articles
 |
Twilight’s Christian Serratos Gets Naked For PETA
Serratos poses naked for the 'I'd Rather Go Naked Than Wear Fur' campaign.
|
 |
30 Greenest Celebs
See which celebrities are giving back to their Mother Earth.
|
 |
Injured Celebrities
Check out stars who've taken a few blows.
|
